Tenvir
$ 52,00 – $ 140,00Price range: $ 52,00 through $ 140,00
Tetracin
$ 19,00 – $ 65,00Price range: $ 19,00 through $ 65,00
Tenvir-EM
$ 82,00 – $ 219,00Price range: $ 82,00 through $ 219,00
Tenvir-EM is a powerful combination medication containing emtricitabine and tenofovir disoproxil fumarate, specifically formulated for the management of HIV-1 infection. This antiretroviral therapy works by effectively blocking the enzymes that the virus needs to replicate and spread throughout the body. When used as part of a comprehensive treatment plan, it helps maintain a low viral load and supports overall immune system health. Furthermore, Tenvir-EM is an established choice for Pre-Exposure Prophylaxis (PrEP) to significantly reduce the risk of sexually acquired HIV-1 in at-risk populations. This high-quality generic medication provides a dependable and accessible option for long-term viral suppression and preventative care.
Active substance: Emtricitabine, Tenofovir Disoproxil Fumarate
SKU:
Tenvir-EM
Categories: AntiVirals, HIV
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Tenvir-EM belongs to a class of combination antiretroviral agents comprising two distinct nucleoside and nucleotide reverse transcriptase inhibitors. In the United States, this prescription-only oral medication contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate per tablet. It is dispensed under applicable federal and state regulations for managing human immunodeficiency virus type 1 (HIV-1) infection and for HIV-1 pre-exposure prophylaxis.
Therapy with this combination product requires a formal prescription, comprehensive baseline testing, and ongoing clinical supervision by a qualified healthcare professional. Patients must strictly follow their prescribed regimen to maintain therapeutic efficacy and reduce the likelihood of viral resistance.
| Attribute | Details |
|---|---|
| Active Ingredients | Emtricitabine (200 mg), Tenofovir disoproxil fumarate (300 mg) |
| Therapeutic Class | Antiretroviral agent, NRTI/NtRTI combination |
| Dosage Form | Oral film-coated tablet |
| Route of Administration | Oral |
| Prescription Status | Prescription (Rx) only |
| Primary Purpose | HIV-1 treatment (in combination therapy) and HIV-1 PrEP |
Clinical Indications and Pharmacological Profile
Mechanism of Action
The active components of Tenvir-EM–emtricitabine and tenofovir disoproxil fumarate–inhibit the activity of HIV-1 reverse transcriptase, an enzyme essential for viral replication. Emtricitabine is a synthetic nucleoside analog of cytidine, while tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate analog of adenosine monophosphate. Once inside host cells, both drugs undergo intracellular phosphorylation to form their active metabolites: emtricitabine triphosphate and tenofovir diphosphate. These active forms compete with natural cellular substrates (deoxycytidine 5′-triphosphate and deoxyadenosine 5′-triphosphate, respectively) for binding to viral reverse transcriptase. Upon incorporation into the growing viral DNA strand, they cause premature DNA chain termination, preventing the virus from replicating and integrating into the host genome. In the setting of pre-exposure prophylaxis (PrEP), this dual inhibition stops HIV-1 from establishing systemic infection following exposure.
Indications and Approved Uses
Tenvir-EM is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg. It is also indicated for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in uninfected individuals weighing at least 35 kg who are at high risk. Before initiating PrEP, individuals must have a documented negative HIV-1 test to avoid inducing drug resistance. Off-label use: This combination tablet may be utilized as part of non-occupational post-exposure prophylaxis (nPEP) protocols when prescribed by a healthcare provider alongside an appropriate third antiretroviral agent, though such use relies on clinical treatment guidelines rather than dedicated FDA labeling.
Pharmacokinetics and Metabolic Pathway
Following oral administration, emtricitabine and tenofovir disoproxil fumarate are rapidly absorbed. Emtricitabine reaches peak plasma concentrations within 1 to 2 hours post-dose. Tenofovir disoproxil fumarate is a prodrug that undergoes rapid biotransformation into tenofovir in plasma and tissue, achieving peak plasma levels within approximately 1 hour under fasting conditions. Neither drug is extensively metabolized by liver cytochrome P450 enzymes, reducing the potential for metabolic drug-drug interactions involving CYP pathways. Elimination occurs primarily through renal excretion via a combination of glomerular filtration and active tubular secretion. The elimination half-life of emtricitabine in plasma is approximately 10 hours, while tenofovir exhibits a plasma half-life of about 17 hours, supporting a convenient once-daily dosing regimen.
Administration, Safety, and Special Guidelines
Dosage and Administration Instructions
The standard dosage for adults and pediatric patients weighing at least 35 kg is one tablet taken orally once daily. Tablets should be swallowed whole with an adequate volume of liquid. For patients with impaired renal function, dosage interval adjustments are necessary if calculated creatinine clearance falls between 30 and 49 mL/min. Tenvir-EM is not recommended for individuals with a creatinine clearance below 30 mL/min or those requiring hemodialysis. Serum creatinine, estimated creatinine clearance, urine glucose, and urine protein must be evaluated prior to initiating therapy and monitored periodically during treatment.
If You Skip a Dose
Maintaining strict adherence to the once-daily schedule is essential for achieving therapeutic goals and preventing the development of drug-resistant HIV-1 strains. If a dose is missed, the patient should take it as soon as remembered on the same day. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients must never take two doses simultaneously to make up for a missed tablet. If multiple doses are missed, the prescribing physician should be contacted immediately for clinical guidance.
Food and Alcohol Interactions
Tenvir-EM may be administered with or without food. Administration of tenofovir disoproxil fumarate with a high-fat meal increases its systemic bioavailability, enhancing tenofovir AUC (area under the curve) by approximately 40%. Emtricitabine exposure remains clinically unaffected by food intake. Alcohol does not directly interfere with the pharmacokinetic disposition of either active drug component; however, heavy alcohol consumption can compromise treatment adherence and increase hepatic stress. Patients are advised to limit alcohol consumption while undergoing antiretroviral therapy.
Important Precautions and Warnings
This medication carries serious warnings regarding acute exacerbations of hepatitis B virus (HBV). Patients co-infected with HIV-1 and HBV who discontinue Tenvir-EM may experience severe acute exacerbations of hepatitis; liver function must be closely monitored for several months following treatment cessation. In individuals using the medication for PrEP, treatment must only be started after confirming a negative HIV-1 status, as unconfirmed acute HIV-1 infection can lead to viral resistance. Additional precautions include potential renal impairment, including acute renal failure and Fanconi syndrome, as well as reductions in bone mineral density. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with nucleoside analog use.
Compatibility with Other Medicines
Tenvir-EM should not be co-administered with other medications containing emtricitabine, tenofovir disoproxil fumarate, tenofovir alafenamide, or lamivudine. Concurrent use with nephrotoxic agents–such as high-dose nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, or vancomycin–increases the risk of renal injury. Co-administration with HCV regimens containing ledipasvir/sofosbuvir can increase tenofovir plasma concentrations, necessitating close monitoring for tenofovir-associated toxicities. Protease inhibitors like atazanavir or darunavir may require pharmacokinetic boosting agents and can alter tenofovir levels, requiring careful clinical management.
Adverse Reactions and Side Effects
Common adverse reactions documented in clinical trials include headache, diarrhea, nausea, fatigue, dizziness, depression, abnormal dreams, and skin rash. Common laboratory abnormalities include elevated serum creatine kinase, hyperamylasemia, increased liver enzymes (AST/ALT), and hypophosphatemia. Less frequent but serious side effects involve renal tubular impairment, decreased bone mineral density at the lumbar spine and hip, and immune reconstitution inflammatory syndrome in HIV-1 infected individuals initiating combination antiretroviral therapy. Patients experiencing persistent gastrointestinal discomfort or unexplained fatigue should consult their healthcare provider.
Storage and Expiration Guidelines
Store the medication at controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F) according to USP guidelines. Keep the tablets in their original container with the desiccant canister tightly closed to protect from moisture. Do not transfer tablets to unsealed pill boxes for extended periods. Store out of the reach and sight of children. Safely discard any unused medication after the expiration date printed on the container label.
Emergency Precautions and FAQs
When to Seek Emergency Care
Immediate emergency medical assistance is required if signs of lactic acidosis or severe hypersensitivity occur. Symptoms such as unexplained deep or rapid breathing, severe nausea, abdominal pain, cold hands and feet, or acute jaundice require urgent evaluation.
| Emergency Indicator | Recommended Action |
|---|---|
| Deep, rapid breathing, muscle pain, cold extremities (Lactic Acidosis) | Seek immediate emergency room evaluation |
| Swelling of face, lips, tongue, or difficulty breathing | Call 911 or go to emergency department immediately |
| Yellowing of skin or eyes, dark urine (Hepatic Dysfunction) | Contact prescribing physician urgently |
| Significant decrease in urination or severe flank pain | Seek prompt medical assessment for acute renal impairment |
Frequently Asked Questions
Q: Is Tenvir-EM approved for post-exposure prophylaxis (PEP)?
A: While Tenvir-EM is officially FDA-approved for HIV-1 treatment and pre-exposure prophylaxis (PrEP), public health guidelines frequently incorporate this combination off-label into 28-day post-exposure prophylaxis (PEP) regimens following potential occupational or non-occupational HIV exposure. PEP protocols require initiation within 72 hours of exposure under medical direction.
Q: How often should renal function be monitored during treatment?
A: Healthcare providers typically evaluate serum creatinine, estimated creatinine clearance, and urine protein prior to starting therapy. For patients without pre-existing renal risk factors, monitoring is generally repeated every 3 to 6 months. Patients with baseline renal risk require more frequent assessment.
Q: What happens if a patient with HIV and hepatitis B co-infection stops taking this drug?
A: Discontinuing therapy can trigger a severe acute flare-up of hepatitis B virus (HBV). Patients with HBV co-infection who cease treatment must be monitored clinically and via laboratory testing for several months post-discontinuation to detect signs of hepatic decompensation.
Q: Does Tenvir-EM interact with common over-the-counter pain relievers?
A: Chronic or high-dose use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen can increase renal strain and the risk of kidney toxicity when taken concurrently with tenofovir disoproxil fumarate. Occasional short-term use may be acceptable, but consult a pharmacist or physician prior to regular use.
Q: Can bone density changes occur during long-term therapy?
A: Decreases in bone mineral density (BMD) have been observed in clinical studies involving tenofovir disoproxil fumarate. Bone density monitoring may be considered for patients with a history of pathologic fractures or significant risk factors for bone loss or osteoporosis.
In accordance with FDA requirements.
Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.
Additional information
| Dosage |
300 mg + 200 mg |
|---|---|
| Package |
30 tabs ,60 tabs ,90 tabs |
| Ενεργός Ουσία | , |
Related products
Adalat
$ 41,00 – $ 267,00Price range: $ 41,00 through $ 267,00
Active substance: Nifedipine
More Details
This product has multiple variants. The options may be chosen on the product page
Amantadine
$ 19,00 – $ 249,00Price range: $ 19,00 through $ 249,00
Active substance: Amantadine
More Details
This product has multiple variants. The options may be chosen on the product page
Medex
$ 41,00 – $ 144,00Price range: $ 41,00 through $ 144,00
Active substance: Coumadin
More Details
This product has multiple variants. The options may be chosen on the product page
Molnupiravir
$ 229,00 – $ 706,00Price range: $ 229,00 through $ 706,00
Active substance: Molnupiravir
More Details
This product has multiple variants. The options may be chosen on the product page
Movfor
$ 293,00 – $ 1 097,00Price range: $ 293,00 through $ 1 097,00
Active substance: Molnupiravir
More Details
This product has multiple variants. The options may be chosen on the product page
Procardia
$ 28,00 – $ 269,00Price range: $ 28,00 through $ 269,00
Active substance: Nifedipine
More Details
This product has multiple variants. The options may be chosen on the product page
Sustiva
$ 47,00 – $ 2 412,00Price range: $ 47,00 through $ 2 412,00
Active substance: Efavirenz
More Details
This product has multiple variants. The options may be chosen on the product page
Zovirax
$ 52,00 – $ 587,00Price range: $ 52,00 through $ 587,00
Active substance: Acyclovir
More Details
This product has multiple variants. The options may be chosen on the product page
